1.
|
18 p, 1.8 MB |
Serum DNA methylome of the colorectal cancer serrated pathway enables non-invasive detection
/
Gallardo-Gómez, María (Universidade de Vigo) ;
Costas-Ríos, Lara (Universidade de Vigo) ;
García-Prieto, Carlos A (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Álvarez-Rodríguez, Lara (Universidade de Vigo) ;
Bujanda, Luis (Universidad del País Vasco (UPV/EHU)) ;
Barrero, Maialen (Hospital Universitario Donostia) ;
Castells, Antoni (Hospital Clínic i Provincial de Barcelona) ;
Balaguer, Francesc (Hospital Clínic i Provincial de Barcelona) ;
Jover, Rodrigo (Universidad Miguel Hernández, Alicante) ;
Esteller, Manel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Tardío Baiges, Antoni (Instituto de Investigación Biomédica Galicia Sur) ;
González-Carreró Fojón, Joaquín (Instituto de Investigación Biomédica Galicia Sur) ;
Cubiella, Joaquín (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Ourense) ;
De Chiara, Loretta (Universidade de Vigo)
The clinical relevance of the colorectal cancer serrated pathway is evident, but the screening of serrated lesions remains challenging. We aimed to characterize the serum methylome of the serrated pathway and to evaluate circulating cell-free DNA (cfDNA) methylomes as a potential source of biomarkers for the non-invasive detection of serrated lesions. [...]
2023 - 10.1002/1878-0261.13573
Molecular Oncology, 2023
|
|
2.
|
17 p, 4.7 MB |
Serum methylation of GALNT9, UPF3A, WARS, and LDB2 as noninvasive biomarkers for the early detection of colorectal cancer and advanced adenomas
/
Gallardo-Gómez, María (Universidade de Vigo) ;
Rodríguez-Girondo, Mar (Department of Medical Statistics and Bioinformatics. Leiden University Medical Centre) ;
Planell, Núria (Universidad Pública de Navarra) ;
Moran, Sebastián (Institut d'Investigació Biomèdica de Bellvitge) ;
Bujanda, Luis (Universidad del País Vasco. Instituto de Investigación Sanitaria Biodonostia) ;
Etxart, Ane (Department of Surgery. Hospital Universitario Donostia) ;
Castells, Antoni (Universitat de Barcelona) ;
Balaguer, Francesc (Universitat de Barcelona) ;
Jover, Rodrigo (Servicio de Medicina Digestiva. Universidad Miguel Hernández) ;
Esteller, M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cubiella, Joaquin (Department of Gastroenterology. Complexo Hospitalario Universitario de Ourense. Instituto de Investigación Biomédica Galicia Sur. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Gómez-Cabrero, David (Mucosal & Salivary Biology Division. King's College London Dental Institute) ;
De Chiara, Loretta (Galicia Sur Health Research Institute) ;
Universitat Autònoma de Barcelona
Background: Early detection has proven to be the most effective strategy to reduce the incidence and mortality of colorectal cancer (CRC). Nevertheless, most current screening programs suffer from low participation rates. [...]
2023 - 10.1186/s13148-023-01570-1
Clinical Epigenetics, Vol. 15 Núm. 1 (december 2023) , p. 157
|
|
3.
|
21 p, 9.8 MB |
Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors
/
Mira, Alessia (Candiolo Cancer Institute) ;
Morello, Virginia (University of Torino Medical School) ;
Céspedes, María Virtudes (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Perera, Timothy (OCTIMET Oncology Ltd) ;
Comoglio, Paolo M. (Candiolo Cancer Institute) ;
Mangues, Ramon 1957- (Institut d'Investigació Biomèdica Sant Pau) ;
Michieli, Paolo (University of Torino Medical School) ;
Universitat Autònoma de Barcelona
The role of paracrine Hepatocyte Growth Factor (HGF) in the resistance to angiogenesis inhibitors (AIs) is hidden in xenograft models because mouse HGF fails to fully activate human MET. To uncover it, we compared the efficacy of AIs in wild-type and human HGF knock-in SCID mice bearing orthotopic human colorectal tumors. [...]
2017 - 10.18632/oncotarget.16942
Oncotarget, Vol. 8 Núm. 24 (2017) , p. 38193-38213
|
|
4.
|
13 p, 1.8 MB |
Lymph Node Molecular Analysis with OSNA Enables the Identification of pT1 CRC Patients at Risk of Recurrence : A Multicentre Study
/
Saez de Gordoa, Karmele (Hospital Clínic i Provincial de Barcelona) ;
Rodrigo-Calvo, Maria Teresa (Hospital Clínic i Provincial de Barcelona) ;
Archilla, Ivan (Hospital Clínic i Provincial de Barcelona) ;
Lopez-Prades, Sandra (Hospital Clínic i Provincial de Barcelona) ;
Díaz, Alba (Hospital Clínic i Provincial de Barcelona) ;
Tarragona, Jordi (Hospital Arnau de Vilanova (Lleida, Catalunya)) ;
Machado, Isidro (Centro de Investigación Biomédica en Red en Cancer (CIBERONC)) ;
Ruiz Martín, Juan (Virgen de la Salud Hospital, Toledo) ;
Zaffalon, Diana (Consorci Sanitari de Terrassa) ;
Daca-Alvarez, Maria (Hospital Clínic i Provincial de Barcelona) ;
Pellisé, Maria (Hospital Clínic i Provincial de Barcelona) ;
Camps, Jordi (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Cuatrecasas, Miriam (Hospital Clínic i Provincial de Barcelona)
Early-stage colorectal carcinoma (CRC)-pT1-is a therapeutic challenge and presents some histological features related to lymph node metastasis (LNM). A significant proportion of pT1 CRCs are treated surgically, resulting in a non-negligible surgical-associated mortality rate of 1. [...]
2023 - 10.3390/cancers15225481
Cancers, Vol. 15 (november 2023)
|
|
5.
|
9 p, 969.5 KB |
SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)
/
Gómez-España, M.A. (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Gallego, J. (Hospital General Universitario de Elche) ;
González-Flores, E. (Hospital Universitario Virgen de las Nieves (Granada)) ;
Maurel, Joan (Hospital Clínic i Provincial de Barcelona) ;
Páez, David (Institut d'Investigació Biomèdica Sant Pau) ;
Sastre, J. (Hospital Clínico San Carlos (Madrid)) ;
Aparicio, J. (Hospital Universitari i Politècnic La Fe (València)) ;
Benavides Orgaz, Manuel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Feliu, J. (Hospital Universitario La Paz (Madrid)) ;
Vera, R. (Complejo Hospitalario de Navarra) ;
Universitat Autònoma de Barcelona
Colorectal cancer (CRC) is the second cause of cancer death in Spain, the objective of this guide published by the Spanish Society of Medical Oncology is to develop a consensus for the diagnosis and management of metastatic disease. [...]
2019 - 10.1007/s12094-018-02002-w
Clinical & Translational Oncology, Vol. 21 Núm. 1 (25 2019) , p. 46-54
|
|
6.
|
11 p, 987.9 KB |
Participants' satisfaction with colorectal cancer screening programs : A systematic review
/
Selva, A. (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Mosconi, Giansanto (University of Pavia) ;
Cacitti, Stefano (Health Protection Agency of Pavia) ;
Odone, Anna (University of Pavia) ;
Pylkkanen, Liisa (University of Turku) ;
Solà, Ivan (Institut d'Investigació Biomèdica Sant Pau) ;
Torà, Núria (Althaia Xarxa Assistencial Universitària de Manresa) ;
Russo, Sara (University of Pavia) ;
Cadum, Ennio (Health Protection Agency of Pavia) ;
Deandrea, Silvia (Health Protection Agency of Pavia) ;
Universitat Autònoma de Barcelona
Since satisfaction with cancer screening experience can increase adherence to programs and contribute to reduce morbidity and mortality, its assessment is crucial for programs' effectiveness. Our aim was to conduct a systematic review about satisfaction of participants with organized colorectal cancer screening. [...]
2023 - 10.1016/j.ypmed.2023.107706
Preventive Medicine, Vol. 175 (october 2023) , p. 107706
|
|
7.
|
11 p, 1.2 MB |
Correlation of recist, computed tomography morphological response, and pathological regression in hepatic metastasis secondary to colorectal cancer : The avamet study
/
Vera, Ruth (Instituto de investigaciones Sanitarias de Navarra (IdISNA)) ;
Gómez, María Luisa (Complejo Hospitalario de Navarra) ;
Ayuso Colella, Juan Ramón (Hospital Clínic i Provincial de Barcelona) ;
Figueras, Joan (Hospital Universitari de Girona Doctor Josep Trueta) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Martínez, Virginia (Hospital Universitario La Paz (Madrid)) ;
Lacasta, Adelaida (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Ruiz-casado, Ana (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Safont, María José (Hospital General Universitario de Valencia) ;
Aparicio Urtasun, Jorge (Hospital Universitari i Politècnic La Fe (València)) ;
Campos, Juan Manuel (Hospital Arnau de Vilanova (València)) ;
Cámara, Juan Carlos (Hospital Universitario Fundación Alcorcón) ;
Martín-Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Montagut Viladot, Clara (Hospital del Mar (Barcelona, Catalunya)) ;
Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Vieitez, Jose María (Hospital Universitario Central de Asturias) ;
Falcó, Esther (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Jorge, Mónica (Hospital Xeral Cíes) ;
Marín, Miguel (Hospital Clínico Universitario de la Arrixaca) ;
Salgado, Mercedes (Complejo Hospitalario de Ourense) ;
Viúdez, Antonio (Instituto de investigaciones Sanitarias de Navarra (IdISNA)) ;
Universitat Autònoma de Barcelona
The prospective phase IV AVAMET study was undertaken to correlate response evaluation criteria in solid tumors (RECIST)-defined response rates with computed tomography-based morphological criteria (CTMC) and pathological response after liver resection of colorectal cancer metastases. [...]
2020 - 10.3390/cancers12082259
Cancers, Vol. 12 Núm. 8 (august 2020) , p. 1-12
|
|
8.
|
24 p, 1.1 MB |
Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019 : Benefits and risks of antithrombotic therapy for cardiovascular disease prevention
/
Walker, Jaqui (International Aspirin Foundation) ;
Cattaneo, Marco (Università degli studi di Milano) ;
Badimon, Lina (Institut d'Investigació Biomèdica Sant Pau) ;
Agnelli, Giancarlo (University of Perugia) ;
Chan, Andrew T. (Harvard Medical School) ;
Lanas, Angel (Universidad de Zaragoza) ;
Rocca, Bianca (Catholic University School of Medicine) ;
Rothwell, Peter (Centre for the Prevention of Stroke and Dementia) ;
Patrignani, Paola ('G.d'Annunizio' University) ;
Langley, Ruth (MRC Clinical Trials Unit at UCL) ;
Vilahur, Gemma (Institut d'Investigació Biomèdica Sant Pau) ;
Cosentino, Francesco (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Universitat Autònoma de Barcelona
At the 2019 International Aspirin Foundation Scientific Conference 'Benefits and Risks of Antithrombotic Therapy for Cardiovascular Disease Prevention', held in Rome, Italy, international experts sought to discuss and debate the optimal antithrombotic strategy for the secondary prevention of cardiovascular disease (CVD) and to seek agreement around dosing and target populations for aspirin use in primary disease prevention. [...]
2020 - 10.3332/ECANCER.2019.998
ecancermedicalscience, Vol. 14 (13 2020) , p. 998
|
|
9.
|
7 p, 468.8 KB |
ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients
/
Riera, Pau (Institut d'Investigació Biomèdica Sant Pau) ;
Artigas-Baleri, Alícia (Institut d'Investigació Biomèdica Sant Pau) ;
Salazar, Juliana (Institut d'Investigació Biomèdica Sant Pau) ;
Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Virgili Manrique, Anna Cristina (Institut d'Investigació Biomèdica Sant Pau) ;
Arranz, María Jesús (Fundació Docència i Investigació Mútua Terrassa) ;
Páez, David (Instituto de Salud Carlos III) ;
Universitat Autònoma de Barcelona
Irinotecan is widely used in the treatment of metastatic colorectal cancer (mCRC) despite its severe toxicities. Toxicity is often associated with the UGT1A1*28/*28 genotype. An explanation for idiopathic toxicity beyond the UGT1A1 biomarker, however, remains a major concern for clinicians. [...]
2020 - 10.3389/fphar.2020.00973
Frontiers in Pharmacology, Vol. 11 (30 2020) , p. 973
|
|
10.
|
12 p, 1.7 MB |
Role of POLE and POLD1 in familial cancer
/
Mur, Pilar (Centro de Investigación Biomédica en Red de Cáncer) ;
García-Mulero, Sandra (Hospital Universitari de Bellvitge) ;
del Valle, Jesús (Centro de Investigación Biomédica en Red de Cáncer) ;
Magraner-Pardo, Lorena (Spanish National Cancer Research Center (CNIO)) ;
Vidal, August (Hospital Universitari de Bellvitge) ;
Pineda, Marta (Centro de Investigación Biomédica en Red de Cáncer) ;
Cinnirella, Giacomo (Hospital Universitari de Bellvitge) ;
Martín-Ramos, Edgar (Universitat de Barcelona) ;
Pons, Tirso (Consell Superior d'Investigacions Científiques) ;
López-Doriga, Adriana (Centro de Investigación Biomédica en Red de Epidemiologia y Salud Pública (CIBERESP)) ;
Belhadj, Sami (Hospital Universitari de Bellvitge) ;
Feliubadaló, Lidia (Centro de Investigación Biomédica en Red de Cáncer) ;
Munoz-Torres, Pau M. (Hospital Universitari de Bellvitge) ;
Navarro, Matilde (Centro de Investigación Biomédica en Red de Cáncer) ;
Grau, Elia (Hospital Universitari de Bellvitge) ;
Darder, Esther (Institut Català d'Oncologia) ;
Llort, Gemma (Consorci Sanitari de Terrassa) ;
Sanz, Judit (Althaia Xarxa Assistencial Universitària de Manresa) ;
Ramon y Cajal, Teresa (Institut d'Investigació Biomèdica Sant Pau) ;
Balmaña Gelpí, Judith (Hospital Universitari Vall d'Hebron) ;
Brunet, Joan (Institut Català d'Oncologia) ;
Moreno, Víctor (Universitat de Barcelona) ;
Piulats, Josep M. (Hospital Universitari de Bellvitge) ;
Matías-Guiu, Xavier (Hospital Universitari de Bellvitge) ;
Sanz-Pamplona, Rebeca (Centro de Investigación Biomédica en Red de Epidemiologia y Salud Pública (CIBERESP)) ;
Aligué, Rosa (Universitat de Barcelona) ;
Capellá, G. (Gabriel) (Centro de Investigación Biomédica en Red de Cáncer) ;
Lázaro, Conxi (Centro de Investigación Biomédica en Red de Cáncer) ;
Valle, Laura (Centro de Investigación Biomédica en Red de Cáncer) ;
Universitat Autònoma de Barcelona
Germline pathogenic variants in the exonuclease domain (ED) of polymerases POLE and POLD1 predispose to adenomatous polyps, colorectal cancer (CRC), endometrial tumors, and other malignancies, and exhibit increased mutation rate and highly specific associated mutational signatures. [...]
2020 - 10.1038/s41436-020-0922-2
Genetics in medicine, Vol. 22 Núm. 12 (december 2020) , p. 2089-2100
|
|